Tate (** - Lutathera (Lutetium Lu 177 dotatate) - Various radiopharmaceutical preparations **)

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

Tate (Lutetium Lu 177 dotatate) is a type of medication being studied in clinical trials for certain cancers. It is currently being investigated as a potential treatment option for metastatic colorectal cancer (mCRC) that has not responded to other treatments (refractory mCRC). In the clinical trial NCT04701476, Tate is being used in combination with pembrolizumab (an immunotherapy drug) for patients with refractory mCRC. The goal of this trial is to see if this combination improves overall survival compared to standard treatments like regorafenib or TAS-102. Tate is administered via a procedure called Trans-arterial Tirapazamine Embolization (TATE). It is important to note that Tate is not yet approved for treating colorectal cancer.

Mechanism of Action

Tate is a radiopharmaceutical. It contains lutetium-177, a radioactive isotope, attached to dotatate, a molecule that targets specific receptors found on certain types of cancer cells, including neuroendocrine tumors. The dotatate part helps deliver the radiation directly to the tumor cells. The radiation emitted by lutetium-177 damages the DNA of the cancer cells, leading to their death. In the context of the NCT04701476 trial, Tate is being used in combination with pembrolizumab, which is an immunotherapy drug that helps the body's immune system fight cancer. The specific mechanism of Tate in the context of mCRC is being studied, as it is primarily known for targeting neuroendocrine tumors.

Side Effects

As Tate is an investigational drug in the context of mCRC Specific side effect data from these trials is still being collected and evaluated. Side effects associated with radiopharmaceuticals can include effects on bone marrow (leading to low blood counts) Liver And kidneys. Side effects related to the TATE procedure itself can also occur. Common side effects of pembrolizumab Which is being used in combination with Tate in the trial Can include fatigue Rash Diarrhea Cough Nausea Decreased appetite Vomiting Constipation And abdominal pain. More serious side effects can also occur with pembrolizumab Affecting various organs. Patients participating in clinical trials are closely monitored for any side effects.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT04701476 Phase 2
Recruiting
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
United States, Taiwan

Quick Info

Brand Name** - Lutathera (Lutetium Lu 177 dotatate) - Various radiopharmaceutical preparations **
CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
771 trials
Leucovorin
Other Medications
631 trials
Trifluridine
Other Medications
45 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.